Clinical Trials

US based Neurocrine Biosciences has started a second double-blind, placebo controlled, randomized cross-over Phase II trial to evaluate NBI- 98854. The company is developing NBI-98854 to address the unmet medical needs of patients suffering...

Bionor Pharma is set to initiate a double blinded, randomized and placebo-controlled trial to evaluate HIV-vaccine candidate Vacc-4x in combination with Revlimid.Revlimid is indicated as a treatment for multiple myeloma and anemia due to myelodysplastic syndrome linked with a...

The Cohort Review Committee has approved Scancell to further escalate cancer vaccine SCIB1 dose to 4mg from the current 2mg in the Phase I clinical trial and recruitment of the final group of patients as planned. ...

Aeras and the Oxford-Emergent Tuberculosis Consortium (OETC) have commenced a Phase IIb trial to investigate a new experimental tuberculosis vaccine in TB patients with human immunodeficiency virus (HIV) infection. The trial will evaluate the HIV patients...

US based drug developer Alnylam Pharmaceuticals has concluded an open label, multi-center, dose escalation Phase I trial evaluating ALN-VSP as a treatment for advanced solid tumors with liver involvement. ALN-VSP is a systemically delivered RNAi therapeutic...

Sinapis Pharma has concluded first Phase I clinical trial of oral and IV administration of methamphetamine HCl for the treatment of stroke and traumatic brain injury. The single-center, open-label, randomized, two-period, two-treatment, two-sequence, single dose, crossover...

Bristol-Myers Squibb Company announced results from a second Phase 3 randomized, double blind study demonstrating that YERVOY™ (ipilimumab) prolonged the lives of patients with metastatic melanoma. The data were published today in the New England Journal of Medicine and...